



UCB announces appointment of Sandrine Dufour as new Chief Financial Officer

Brussels (Belgium) March 9, 2020 – 5:30 PM (CET) – UCB today announced the appointment of Sandrine Dufour as Executive Vice President and Chief Financial Officer. Sandrine will be a member of UCB's Executive Committee reporting to Jean-Christophe Tellier, UCB's CEO and Chairman of the Executive Committee. Mrs. Dufour will begin her employment on 1 July 2020.

Mrs. Dufour is a senior executive with a proven track record and deep financial expertise that stems from more than 25 years leading with successful national and global organizations. Since 2015 she held the role of CFO at Proximus, Belgium's largest telecommunication company. Prior to Proximus, Sandrine held several leadership roles at Vivendi, in France and in the US, covering areas including finance and strategy, M&A, innovation and transformation. Before that she held the role of EVP Finance and Strategy at SFR, a leading telecom player in France.

She began her career as a financial analyst. Mrs. Dufour holds several degrees from ESSEC Business School, the Société Française des Analystes Financiers, and the Chartered Financial Analyst (CFA) Institute. She is a Board member of WPP as non-executive director.

Jean-Christophe Tellier, CEO of UCB said, "We are pleased to announce Sandrine Dufour's appointment to Chief Financial Officer. She is joining us at an exciting time as we are accelerating our growth and looking to launch 6 or 7 potential new products by 2025. With her deep financial expertise, sound strategic capabilities and proven leadership, I'm certain that Sandrine is the right person to continue providing a strong financial backbone and guidance."

Sandrine Dufour is taking over from Detlef Thielgen, who has been UCB's CFO since 2007. Mr. Tellier stated: "I'd like to personally thank Detlef for helping UCB navigate through more than a decade of change, helping the company to transform into a biopharma leader, helping to improve the lives of patients across the globe."

Detlef Thielgen will be leaving UCB during the first semester of 2020. As needed Jean-Christophe Tellier will ensure the interim role of CFO until Mrs. Dufour joins on July 1st.

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7 500 people in approximately 40 countries, UCB generated revenue of € 4.9 billion in 2019. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news

For further information –

UCB - Corporate Communications

Laurent Schots,
Media Relations, UCB
T +32.2.559.92.64,
Laurent.schots@ucb.com

UCB - Investor Relations

Antje Witte,
Investor Relations, UCB
T +32.2.559.94.14,
antje.witte@ucb.com

Isabelle Ghellynck,
Investor Relations, UCB
T +32.2.559.9588,
isabelle.ghellynck@ucb.com

Forward looking statements UCB

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees.

Additionally, information contained in this document shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction. UCB is providing this information as of the date of this document and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.

There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.

Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.